62
Participants
Start Date
June 13, 2020
Primary Completion Date
November 16, 2020
Study Completion Date
November 16, 2020
Acalabrutinib
Acalabrutinib administered orally
Research Site, New York
Research Site, The Bronx
Research Site, Albany
Research Site, Buffalo
Research Site, Philadelphia
Research Site, Washington D.C.
Research Site, Bethesda
Research Site, Silver Spring
Research Site, Baltimore
Research Site, Annapolis
Research Site, Richmond
Research Site, Jacksonville
Research Site, Jacksonville
Research Site, Fort Lauderdale
Research Site, Loxahatchee Groves
Research Site, Anniston
Research Site, Mobile
Research Site, Nashville
Research Site, Louisville
Research Site, Fort Wayne
Research Site, Tyler
Research Site, Houston
Research Site, Houston
Research Site, Glendale
Research Site, Escondido
Research Site, Newport Beach
Research Site, Fullerton
Research Site, Renton
Research Site, New Haven
Research Site, Bethesda
Research Site, Hackensack
Lead Sponsor
Collaborators (1)
Acerta Pharma BV
INDUSTRY
AstraZeneca
INDUSTRY